Brief: Akari Therapeutics Says Nomacopan Receives Orphan Drug Designation From European Commission
27/07/2023 14:59
July 27 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS - GRANTED NOMACOPAN ORPHAN DRUG
DESIGNATION
FROM EUROPEAN COMMISSION FOR TREATMENT IN HEMATOPOIETIC STEM
CELL TRANSPLANTATION
* AKARI THERAPEUTICS - MOVING FORWARD INTO PHASE 3 TRIAL OF
NOMACOPAN IN ADULT HSCT-TMA WITH ENROLLMENT EXPECTED TO BEGIN IN
2024
Further company coverage: AKTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics